During the past decade, Shimane University Hospital conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 9 clinical trials were completed, i.e. on average, 40.9% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 8 clinical trials were completed. i.e. 133.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Shimane University Hospital" #1 sponsor was "Eli Lilly and Company" with 5 trials, followed by "Janssen Research & Development, LLC" with 3 trials sponsored, "Chugai Pharmaceutical" with 2 trials sponsored, "Japan Rhabdomyosarcoma Study Group" with 2 trials sponsored and "Pfizer" with 2 trials sponsored. Other sponsors include 13 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Shimane University Hospital" #1 collaborator was "Incyte Corporation" with 2 trials as a collaborator, "Japan Lung Cancer Society" with 2 trials as a collaborator, "Maruishi Pharmaceutical" with 2 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator and "Gilead Sciences" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Shimane University Hospital" are "Atopic Dermatitis" (2 trials), "Psoriasis" (2 trials), "Sarcoma" (2 trials), "Sedation" (2 trials) and "Ulcerative Colitis" (2 trials). Many other conditions were trialed in "Shimane University Hospital" in a lesser frequency.

Most popular intervention types in "Shimane University Hospital" are "Drug" (28 trials), "Biological" (3 trials), "Radiation" (2 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Baricitinib" (2 trials), "Guselkumab" (2 trials), "Mirikizumab" (2 trials) and "Ustekinumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Shimane University Hospital" are 30 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Shimane University Hospital". undefined are not yet recruiting, 3 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in Shimane University Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Shimane University Hospital, 2 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".

Shimane University Hospital has several departments that took part in Clinical trials: "Shimane University Faculty of Medicine" - 4 trials